U.S. pharma huge copyright scrapped two experimental weight loss tablets last year—a after-day by day pill, lotiglipron, resulting from elevated liver enzymes in addition to a 2 times-every day tablet, danuglipron, because of powerful side effects—but CEO Albert Bourla has said the company is determined to “play and gain” inside the being o